Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Dietrich, Sascha [VerfasserIn]   i
 Tielesch, Blanca [VerfasserIn]   i
 Rieger, Michael [VerfasserIn]   i
 Nickelsen, Maike [VerfasserIn]   i
 Pott, Christiane [VerfasserIn]   i
 Witzens-Harig, Mathias [VerfasserIn]   i
 Kneba, Michael [VerfasserIn]   i
 Schmitz, Norbert [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
 Dreger, Peter [VerfasserIn]   i
Titel:Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma
Verf.angabe:Sascha Dietrich, Blanca Tielesch, Michael Rieger, Maike Nickelsen, Christiane Pott, Mathias Witzens-Harig, Michael Kneba, Norbert Schmitz, Antony D. Ho, and Peter Dreger
E-Jahr:2011
Jahr:May 1, 2011
Umfang:10 S.
Fussnoten:First published: 29 November 2010 ; Gesehen am 10.06.2022
Titel Quelle:Enthalten in: Cancer
Ort Quelle:New York, NY : Wiley-Liss, 1948
Jahr Quelle:2011
Band/Heft Quelle:117(2011), 9, Seite 1901-1910
ISSN Quelle:1097-0142
Abstract:BACKGROUND: Autologous stem cell transplantation (autoSCT) has improved the outcome of patients with mantle cell lymphoma (MCL) considerably. However, little is known about the patterns and outcome of MCL recurrence after autoSCT. METHODS: The authors conducted a retrospective study of 118 patients with MCL who underwent autoSCT from August 1992 to August 2008 at 3 different referral centers in Germany. RESULTS: Fifty-two relapses occurred for a cumulative incidence of 46% after 5 years. Only 3 patients relapsed after 5 years (at 90 months, 91 months, and 171 months) after undergoing autoSCT. A Cox regression analysis of the incidence of relapse identified not receiving rituximab before autoSCT and undergoing salvage autoSCT as predictive factors for relapse, whereas cytosine arabinoside intensification; a total body irradiation-based, high-dose regimen; patient age; and year of transplantation had no influence. The median overall survival (OS) after relapse was 23 months. Twenty patients (39%) underwent allogeneic stem cell transplantation (alloSCT) for relapse, and 11 of those patients remained in ongoing complete remission at the time of the current report. It is noteworthy that there were 4 long-term survivors who lived for >5 years after relapse even without undergoing alloSCT. A Cox regression analysis of OS after relapse revealed that the response duration after autoSCT was an adverse predictor of OS, whereas alloSCT was associated with a significantly longer OS after relapse. CONCLUSIONS: The current results indicated that autoSCT was capable of inducing long-term remission up to 16 years after treatment, but the outcome of patients with MCL who relapsed after autoSCT was poor, especially if their response duration after autoSCT was short. However, for a subset of patients with relapsed MCL, alloSCT may offer the possibility of durable survival, and individual patients can enjoy long-term survival after relapse even without undergoing alloSCT. Cancer 2011. © 2010 American Cancer Society.
DOI:doi:10.1002/cncr.25756
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1002/cncr.25756
 Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.25756
 DOI: https://doi.org/10.1002/cncr.25756
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:allogeneic stem cell transplantation
 autologous stem cell transplantation
 mantle cell lymphoma
 relapse
 rituximab
K10plus-PPN:1806781417
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68929719   QR-Code
zum Seitenanfang